Imported Fluorosilicone Oil Prices Surge 30% with Shortages, Domestic Substitutes See Explosive Growth

Recently, the domestic medical device and high-end manufacturing sectors have witnessed significant industry changes. The prices of imported fluorosilicone oil have been rising continuously with tight supply, bringing great pressure to related enterprises. At the same time, domestic fluorosilicone oil has achieved rapid growth in market share with its stable performance and cost advantages, accelerating the process of domestic substitution. It is reported that since 2025, the global silicone market has ushered in a new round of price increases. International giants such as Dow Chemical and Wacker Chemie have successively raised the prices of silicone products. Among them, the price of imported fluorosilicone oil (such as Nusil MED-420 series) has increased by more than 30%, and the mainstream quotation of silicone oil has exceeded 15,500-16,100 yuan/ton, an increase of more than 1,000 yuan/ton compared with the beginning of the year. Affected by the geopolitical conflicts in the Middle East, the prices of raw materials such as methanol have soared, and the cost pressure of the silicone industrial chain has been continuously transmitted. Coupled with the tense international trade situation, the delivery cycle of imported high-end fluorosilicone oil has been extended from the original 2-4 weeks to 8-12 weeks. Some brands even implement a quota system, leaving small and medium-sized medical device enterprises facing the dilemma of "unable to buy even with money". Against this background, domestic fluorosilicone oil enterprises have ushered in development opportunities. Taking Baoxing BX51000 fluorosilicone oil as an example, its performance is comparable to that of imported Nusil MED-420. It has passed the full set of ISO 10993 biocompatibility tests, with a temperature resistance range of -50℃~300℃. It performs better in high temperature resistance and material compatibility, and its product price is only 50%-70% of that of imported products, with the comprehensive cost reduced by 40%-50%. At present, many medical device manufacturers have switched to this domestic product in batches. In scenarios such as the molding of medical catheter tips, the demolding success rate has increased from 96.5% to 98.2%, and the scrap rate has dropped significantly. Industry data shows that in the 2024 Chinese medical fluorosilicone oil market, the domestic share has increased from 15% in 2019 to 45%, and it is expected to exceed 60% in 2026. In fields such as catheters and syringes, the domestic substitution rate has exceeded 70%. With the strong support of national policies for the localization of key raw materials for high-end medical devices and the continuous breakthroughs in technology of domestic enterprises, the domestic substitution of fluorosilicone oil has become an irresistible trend, which will provide a stable guarantee for the development of the domestic high-end manufacturing industry.